OCT 18, 2019 11:00 AM PDT

AcroMetrix BCR-ABL External Molecular Panel: An Accurate Testing Method for Chronic Myeloid Leukemia

WRITTEN BY: Nupur Srivastava

To support the validation and verification of new assays and to challenge the existing assays in oncology testing, Thermo Fisher Scientific launches Thermo Scientific Acrometrix BCR-ABL Panel. The product provides innovative standards for analytical BCR-ABL test methods in chronic myeloid leukemia (CML) disease. 

Chronic myeloid leukemia (CML) is a cancer of the blood-forming cells, called myeloid cells, found in the bone marrow. In CML, the bone marrow produces more white blood cells that usually are involved in fighting infection. 

BCR-ABL1 is a gene sequence that confirms the diagnosis of Chronic Myeloid Leukemia (CML), persistent bone marrow cancer. The detected gene is present in abnormal chromosome 22 of humans. In CML, part of chromosome 9 breaks off and bonds to a section of chromosome 22, forming the fusion chromosome. The abnormal BCR-ABL1 gene encodes an abnormal protein (tyrosine kinase) that is responsible for the development of CML.

Different testing types (cytogenetics, fluorescence in-situ hybridization, genetic molecular) are available to diagnose CML. The Acrometrix BCR-ABL external control panel is launched to quantitate BCR-ABL RNA accurately. The first of its kind, the product is useful to make a critical, timely, patient treatment decisions. The test product intends for research-use-only. The testing method can monitor assay performance at every clinical stage due to its expanded dynamic range.

"The Acrometrix BCR-ABL Panel is the first full-process molecular control for challenging validated BCR-ABL assay performance, providing researchers and laboratorians with greater confidence utilizing a highly characterized product," said Fernando Beils, vice president and general manager of Clinical Diagnostics for Thermo Fisher. "Additionally, this new molecular control panel is traceable to the new World Health Organization (WHO) standards for genetic reference panels for the quantitation of BCR-ABL. This provides assurance to laboratory staff that there is accuracy in the measurement of their assay results."

Sources: AmericanCancerSociety, ThermoFisherScientific

About the Author
You May Also Like
AUG 04, 2019
Immunology
AUG 04, 2019
New Research In Reversing Deafness
Hair cells inside the human ear are responsible for sensing and relaying sound to the brain.  In all mammals except humans, these cells can regenerate...
SEP 15, 2019
Immunology
SEP 15, 2019
New Observations of a Cancer Transcriptase
New research shows a transcriptase that helps time cell death varies in expression, and is unusually localized, in cancer cells.  The transcriptase, T...
OCT 24, 2019
Clinical & Molecular DX
OCT 24, 2019
Patients can Self-Inject Easily Using an Integrated Pre-Filled Syringe and Autoinjector
The patients suffering from chronic disease require a regular dose of medicines, either orally or as injections. To prevent a monthly visit...
NOV 20, 2019
Clinical & Molecular DX
NOV 20, 2019
New diagnostic technology seeks out cancer DNA in blood
For many cancers, early detection has a tremendous impact on patient outcomes. Yet, sadly, many of the most common malignancies, like those of the stomach,...
NOV 14, 2019
Cell & Molecular Biology
NOV 14, 2019
Scientists Find a Non-Invasive Way to Detect Prions
Misfolded proteins, also called prions, can cause a host of problems, including neurodegenerative disorders....
DEC 02, 2019
Cannabis Sciences
DEC 02, 2019
Scientists List Several Reasons Not to Use Marijuana During Pregnancy
An estimated 16 percent of women use marijuana on a daily basis while pregnant, and a large majority of women do so without realizing the potential health...
Loading Comments...